Cytochroma gets $45M in third round

CompanyAmount/RoundLead InvestorsDescription
$45 million
Mitsubishi Tanabe Pharma Corporation

The money will be used to advance Cytochroma's portfolio of vitamin D-based therapeutics into mid- and late-stage clinical trials.

Tetraphase Pharmaceuticals
Mediphase Venture Partners, CMEA Ventures, Fidelity Biosciences, Flagship Ventures and Skyline Ventures

Tetraphase will use the funding to support the advancement of several antibiotic drug candidates.

Celator Pharmaceuticals
New Jersey
Domain Associates, Ventures West, Quaker BioVentures, TL Ventures, GrowthWorks Capital, and BDC Capital

The money will be used to finance mid-stage studies of CPX-351 for acute myeloid leukemia.

Sierra Neuropharmaceuticals
HealthCare Ventures, Morgenthaler Ventures, and Sequel Venture Partners

Sierra, which is based in Colorado, plans to formulate drugs that can be delivered directly to the fluid around the brain in order to provide more effective treatment for severe CNS diseases like epilepsy, depression and schizophrenia.

Cytochroma gets $45M in third round

Suggested Articles

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.

Since Takeda bought out Shire, it’s lost a number of high-ranking research execs from the Irish rare disease biotech; it’s also losing one of its own.

Just a few months after a series B-plus worth $75 million, U.S.-China biotech Harbour BioMed has nabbed a major $102.8 million series C.